Quick Answer
Tempest Therapeutics, Inc. reported Operating Income of -$26.57 million for fiscal year 2025.
Tempest Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$26.57M | +36.8% |
| 2024 | -$42.03M | -44.1% |
| 2023 | -$29.16M | +15.8% |
| 2022 | -$34.64M | -28.4% |
| 2021 | -$26.99M | -39.8% |
| 2020 | -$19.30M | +57.5% |
| 2019 | -$45.40M | -68.9% |
| 2018 | -$26.87M | +68.1% |
| 2017 | -$84.33M | -4.1% |
| 2016 | -$81.01M | -12.5% |
| 2015 | -$72.00M | -50.2% |
| 2014 | -$47.93M | -64.5% |
| 2013 | -$29.13M | -115.3% |
| 2012 | -$13.53M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$3.60M | +65.9% | +54.8% |
| June 30, 2025 | -$7.97M | +16.9% | +27.2% |
| March 31, 2025 | -$10.94M | -37.1% | -3.6% |
| September 30, 2024 | -$10.55M | -60.1% | -10.1% |
| June 30, 2024 | -$9.58M | -28.3% | -20.2% |
| March 31, 2024 | -$7.97M | -5.2% | -21.0% |
| September 30, 2023 | -$6.59M | +24.8% | +11.8% |
| June 30, 2023 | -$7.47M | +14.9% | +1.5% |
- Tempest Therapeutics, Inc. showed an increase of +36.8% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, Tempest Therapeutics, Inc.’s operating income has declined by 96.4% (from -$13.53 million to -$26.57 million).
- The most recent figure is from Tempest Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: